Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC Heart Failure Association


Por: Garcia-Pavia, P, Gonzalez-Lopez, E, Anderson, LJ, Cappelli, F, Damy, T, Fontana, M, Gonzalez-Costello, J, Jurcut, R, Lairez, O, van der Meer, P, Merlo, M, Perlini, S and Bayes-Genis, A

Publicada: 1 ene 2026 Ahead of Print: 1 oct 2025
Resumen:
This clinical consensus statement, developed by the Heart Failure Association of the European Society of Cardiology, offers a detailed review of the non-specific management of transthyretin amyloid cardiomyopathy (ATTR-CM). This progressive and often fatal condition is increasingly recognized as a major contributor to heart failure. This document provides advice on symptom management and enhancing quality of life, with a focus on volume management, neurohormonal modulation, and tailored use of diuretics and other supportive therapies that address the distinct pathophysiology of ATTR-CM. It also explores advanced treatment modalities such as heart transplantation and mechanical circulatory support, which play crucial roles in managing advanced stages of the disease. Furthermore, it addresses the management of aortic stenosis in the context of ATTR-CM, advising transcatheter aortic valve replacement as the preferred treatment for these patients. The advice provided in this document relies primarily on expert opinion and retrospective studies due to a notable lack of randomized clinical trials, which underscores a critical research gap and the pressing need for evidence-based treatment protocols.

Filiaciones:
Garcia-Pavia, P:
 Hosp Univ Puerta Hierro Majadahonda, Dept Cardiol, IDIPHISA, GUARD HEART ERN, Manuel de Falla 2, Madrid 28222, Spain

 Inst Salud Carlos III, CIBER Cardiovasc, Madrid, Spain

 Ctr Nacl Invest Cardiovasc CNIC, C Melchor Fernandez Almagro 3, Madrid 28029, Spain

Gonzalez-Lopez, E:
 Hosp Univ Puerta Hierro Majadahonda, Dept Cardiol, IDIPHISA, GUARD HEART ERN, Manuel de Falla 2, Madrid 28222, Spain

 Inst Salud Carlos III, CIBER Cardiovasc, Madrid, Spain

Anderson, LJ:
 St George Hosp, Cardiol Clin Acad Grp, London, England

Cappelli, F:
 Careggi Univ Hosp, Tuscan Reg Amyloidosis Ctr, Florence, Italy

Damy, T:
 APHP CHU Henri Mondor Creteil & Reseau Amylose & F, Referral Ctr Cardiac Amyloidosis, GUARD HEART ERN, Paris, France

 APHP CHU Henri Mondor Creteil & Reseau Amylose & F, Dept Cardiol, GUARD HEART ERN, Paris, France

Fontana, M:
 Royal Free Hosp, Natl Amyloidosis Ctr, Div Med, UCL, London, England

Gonzalez-Costello, J:
 Hosp Univ Bellvitge, Dept Cardiol, Barcelona, Spain

 Inst Invest Biomed Bellvitge, Bioheart, Barcelona, Spain

Jurcut, R:
 Univ Med & Pharm Carol Davila, Bucharest, Romania

 Emergency Inst Cardiovasc Dis Prof dr CC Iliescu, Expert Ctr Rare Cardiovasc Dis, GUARD HEART ERN, Bucharest, Romania

Lairez, O:
 Toulouse Univ, HealthAge Univ Hosp Inst, Toulouse, France

van der Meer, P:
 Expt Cardiol Univ Med Ctr Groningen, Groningen, Netherlands

Merlo, M:
 Azienda Sanit Univ Giuliano Isontina ASUGI, Cardiothoracovasc Dept, GUARD HEART ERN, Trieste, Italy

 Univ Trieste, Azienda Sanit Univ Giuliano Isontina ASUGI, Ctr Diag & Treatment Cardiomyopathies, Cardiovasc Dept, Trieste, Italy

Perlini, S:
 Univ Pavia, IRCCS Policlin San Matteo Fdn, Emergency Med & Amyloidosis Res & Treatment Ctr, Dept Internal Med, Pavia, Italy

:
 Inst Salud Carlos III, CIBER Cardiovasc, Madrid, Spain

 Inst Cor Hosp Univ Germans Trias & Pujol, Badalona 08916, Spain

 Univ Autonoma Barcelona, Dept Med, Barcelona, Spain
ISSN: 15229645





European Heart Journal
Editorial
Oxford University Press, GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND, Reino Unido
Tipo de documento: Review
Volumen: 47 Número: 1
Páginas: 22-36
WOS Id: 001588116100001
ID de PubMed: 41055898
imagen Green Submitted, Bronze

MÉTRICAS